Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANDAMET plus insulin in type 2 diabetes starting insulin therapy
NCT00069836Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2003
- Primary completion
- Nov 2004
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of rosiglitazone in type 2 diabetes mellitus (T2DM), sponsored by GSK. Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started Oct 2003; status: completed.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00069836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00069836.